双pH和微生物敏感的银河化聚合物纳米货物用于多层次的向,以对抗性结肠炎
Mahira Zeeshan1,2,3, Qurat Ul Ain1, Benno Weigmann2
1Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Asian journal of pharmaceutical sciences
|August 17, 2023
概括
新的纳米货物有效地将德克萨米他输送到结肠以治疗性结肠炎 (UC). 这些对双刺激有反应的纳米粒子向炎症区域,增强药物输送并减少结肠炎症状.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于生理障碍,性结肠炎 (UC) 对口服药物输送提出了重大挑战.
- 开发有针对性的药物输送系统对于有效的UC管理至关重要.
研究的目的:
- 开发新的德克萨梅他装载的Galactosylated-PLGA/Eudragit S100/pullulan纳米货物 (Dexa-GP/ES/Pu NCs) 用于针对性结肠输送UC.
- 评估纳米货物的双刺激响应 (pH和微生物群) 和联体介导 (银糖-MGL-2) 准能力.
- 在UC的实验模型中评估Dexa-GP/ES/PuNCs的治疗疗效.
主要方法:
- 纳米货物使用修改后的乳液和溶剂蒸发技术来制备.
- 评估了物理化学性质,药物释放动力学,细胞吸收和细胞毒性.
- 疗效在试验室*,活体外和酸 (DSS) 诱导的大肠炎的小鼠模型中进行了评估.
主要成果:
- 准备好的Dexa-GP/ES/PuNCs表现出有利的物理化学特性和受控的药物释放.
- 观察到增强的巨细胞吸收和特定的结肠局部化.
- 使用Dexa-GP/ES/Pu NCs的治疗显著减轻了结肠炎,降低了炎症标志物 (NF-B,COX-2) 的调节,并恢复了生理参数.
结论:
- 德克萨-GP/ES/PuNCs是生物相容的,并证明有效的向药物输送到炎症结肠.
- 双刺激响应和联体介导向方法提高了UC的治疗结果.
- 这些纳米货物为炎症性肠病中长期和局部药物输送提供了一个有希望的战略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
556
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
556
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
495
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
495
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
250
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
250
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195


